Japanese Journal of Clinical Oncology · 2022 · 11 citations · 16 references
MedicineOncologyPharmacologyCancer PharmacologyImmunotherapyPharmacokinetics Of Anticancer AgentsCancer ImmunotherapyHematologic Malignancy TherapyImmune-related Adverse EventsOral Anticancer Therapy SafetyDose-limiting Toxicity AssessmentEpigenetic Immune ReprogrammingEpigenetic TherapiesHistone DeacetylasesNon-hodgkin Lymphoma TherapyNon-hodgkin Lymphoma TreatmentRefractory Non-hodgkin LymphomaRelapsed Non-hodgkin Lymphoma
OBJECTIVE: HBI-8000 (tucidinostat) is a novel, oral histone deacetylase inhibitor that selectivity inhibits Class I (histone deacetylase 1, 2, 3) and Class II (histone deacetylase 10) with direct anti-tumor activity through various mechanisms of action, including epigenetic reprogramming and immunomodulation. It has been approved in China for the treatment of relapsed or refractory peripheral T-cell lymphoma. METHODS: This multicenter, prospective phase I dose-escalation trial evaluating the safety of twice weekly HBI-8000 was conducted in Japan. Eligible patients had non-Hodgkin's lymphoma and no available standard therapy. The primary endpoint was maximum tolerated dose; secondary endpoints included anti-tumor activity, safety and pharmacokinetics. RESULTS: Fourteen patients were enrolled in the study. Twelve patients were assessed for dose-limiting toxicity: six patients in the 30 mg BIW cohort had no dose-limiting toxicitys; two of six patients in the 40 mg BIW cohort had asymptomatic dose-limiting toxicitys. Treatment was well tolerated; adverse events were predominantly mild to moderate hematologic toxicities and were managed with dose modification and supportive care. Thirteen patients were included in the efficacy analysis. Objective response was seen in five of seven patients in the 40 mg BIW cohort; three partial responders had adult T-cell leukemia-lymphoma. In the 30 mg BIW cohort, three of six patients had stable disease after the first cycle. CONCLUSIONS: Treatment with HBI-8000 30 and 40 mg BIW were well-tolerated and safe, with hematological toxicities as expected from other studies of histone deacetylase inhibitor. The maximum tolerated dose and recommended dosage for phase II studies of HBI-8000 is 40 mg BIW. Preliminary efficacy results are encouraging.
16
Elise A. Olsen, Sean Whittaker, Youn H. Kim et al. · Journal of Clinical Oncology · 2011 · 658 citations · Full text
Medicine, Dermatology, Oncology +17
Kunihiro Tsukasaki, Olivier Hermine, Ali Bazarbachi et al. · Journal of Clinical Oncology · 2008 · 550 citations · Full text
Medicine, Immunology, Oncology +15
Wilko Weichert, A.-E. Roske, Volker Gekeler et al. · British Journal of Cancer · 2008 · 479 citations · Full text